Stephen Huber

In this pipeline report, Dermatology Times presents insights into Hh pathway inhibitors currently in phase 2 and phase 3 for the treatment of basal cell carcinoma. 

Innovative melanoma therapeutics are on the horizon. This pipeline report highlights some of the new drugs currently in phase 2, phase 3 or recently approved for the treatment of melanoma.